Abstract Details

Title Proficient Inhibitory Control in Patients with Parkinson Disease and Impuse Control Disorder

Topic Movement Disorders

Presentation(s) P06 - (-)

Poster/Presentation
Number 094

Objective

Background BACKGROUND: Impulse Control Disorder implies a difficulty suppressing impulses to act. It is thought that DAAs disrupt inhibitory control circuits, thus patients may be less proficient at stopping their actions. We measured the speed of action selection and the speed of action inhibition using the stop-signal task.

Design/Methods DESIGN/METHODS: 14 PD-ICD and 15 PD controls without ICD completed two test sessions, once after withdrawing from DAA for 24 hours. PD-ICD patients were recruited at the time of ICD diagnosis, before reductions of DAA were made. The stop-signal task required participants to press a button with the left or right thumb based on the direction of a left or right pointing arrow. On the 25% of trials, the go arrow turned red shortly after its onset, which instructed participants to stop their button press. The task yields two key dependent measures, Go reaction time (GoRT) and Stop-Signal reaction time (SSRT).

Results RESULTS: Both groups showed similar mean RTs to the go signal. Mean RT to the go signal was similar in the Off and On DAA state. In contrast, the PD-ICD group showed faster inhibition of their reactions (i.e., faster SSRT) compared to PD controls (PD-ICD: SSRT=205 ms; PD: SSRT=237 ms)(Group: F(1,27)=6.32, p=.01). The speed of inhibiting reactions was unaffected by agonist state, a pattern that held across groups.

Conclusions CONCLUSIONS: Contrary to prediction, PD patients with ICD were more proficient at inhibiting their actions compared to PD patients without ICD. Short-term DAA state did not influence the speed of action selection or stopping. These findings suggest that deficient inhibitory control over actions does not contribute to impulse control problems in PD patients taking DAA.

Authors/Disclosures
Daniel O. Claassen, MD, FAAN (Vanderbilt University Medical Center) PRESENTER	Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.
	No disclosure on file
	No disclosure on file
Madaline B. Harrison, MD (UVA - Dept of Neurology)	Dr. Harrison has nothing to disclose.
Stephen D. Silberstein, MD, FAAN	Dr. Silberstein has received publishing royalties from a publication relating to health care.
G. F. Wooten, MD (University of Virginia Health System)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��